bpc 157 and nad I recently embarked on a health experiment: combining NAD+ BPC-157 to support cellular repair, recovery and performance. 🔬 Why I tried it: After years in biotech/medical tech, I've become obsessed with The Truth Behind BPC-157 -

A standard 3.2 mg KLOW dose contains only 400 mcg of full-length TB-4

Over the following weeks most people notice subtle metabolic shifts and reduced bloating first (weeks 12), then more noticeable body-composition change around the midsection (weeks 24), then visible fat loss with muscle preserved (weeks 48), with the best results from week 8 onward, diet and exercise still do the heavy lifting

When AOD 9604 binds to beta-3 adrenergic receptors on white fat cells, it triggers a cascade that starts with adenylyl cyclase activation

None of the retatrutide combinations on this page has established dosing, interaction, long-term safety, or outcome data from a controlled human trial

DOI: 10.1111/acel.14083 Circulation Research (2018) Ahajournals.org Reviewed the roles of SIRT1, SIRT3, SIRT4, SIRT6, SIRT7, and NAD+ across cardiovascular ageing, confirming protective roles against dyslipidaemia, obesity, type 2 diabetes, arrhythmia, cardiac fibrosis, hypertrophy, and ischaemia-reperfusion injury